LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

Home・Lista de Ações・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Abrir

SetorSaúde

31.28 -1.08

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

31.03

Máximo

31.72

Indicadores-chave
By Trading Economics
Rendimento	2.6M -79M
Vendas	-60K 15K
EPS	-1.18
Margem de lucro	-524,566.667
Funcionários	198
EBITDA	-3M -84M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+66.67% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-160M 2.4B
Abertura anterior	32.36
Fecho anterior	31.28

Sentimento de Notícias

By Acuity

38%

62%

106 / 344 Ranking em Healthcare

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de mai. de 2026, 22:47 UTC

Ganhos

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 de mai. de 2026, 20:45 UTC

Ganhos

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 de mai. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 de mai. de 2026, 23:31 UTC

Conversa de Mercado

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 de mai. de 2026, 23:02 UTC

Conversa de Mercado

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 de mai. de 2026, 22:41 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 de mai. de 2026, 22:41 UTC

Conversa de Mercado

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 de mai. de 2026, 22:37 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 de mai. de 2026, 22:04 UTC

Aquisições, Fusões, Aquisições de Empresas

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 de mai. de 2026, 22:04 UTC

Aquisições, Fusões, Aquisições de Empresas

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 de mai. de 2026, 21:12 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 de mai. de 2026, 21:00 UTC

Ganhos

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 de mai. de 2026, 20:57 UTC

Ganhos

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 de mai. de 2026, 20:55 UTC

Ganhos

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

28 de mai. de 2026, 20:48 UTC

Ações em Alta

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 de mai. de 2026, 20:34 UTC

Ganhos

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 de mai. de 2026, 20:31 UTC

Ganhos

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 de mai. de 2026, 20:28 UTC

Ganhos

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 de mai. de 2026, 20:26 UTC

Ganhos

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 de mai. de 2026, 20:20 UTC

Ganhos

Costco 3Q Membership Fees $1.37B

28 de mai. de 2026, 20:20 UTC

Ganhos

Costco 3Q Net Sales $69.15B

28 de mai. de 2026, 20:19 UTC

Ganhos

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 de mai. de 2026, 20:19 UTC

Ganhos

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 de mai. de 2026, 20:17 UTC

Ganhos

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 de mai. de 2026, 20:17 UTC

Ganhos

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

66.67% parte superior

Previsão para 12 meses

Média 52.75 USD 66.67%

Máximo 67 USD

Mínimo 38 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

Comprar

Manter

Vender

Com base em 9 analistas que deram avaliações de ações para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

106 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.